Glycomine

Glycomine develops replacement therapies for serious rare genetic diseases, many of which have no disease-modifying treatment options. Its approach addresses protein dysfunction caused by genetic mutations by replacing a protein or delivering a substrate or enzyme that bypasses the deficient protein. The company then uses its platform to deliver the therapy to clinically relevant cells and organ systems, building a pipeline intended to address a range of rare diseases and unmet patient needs.